When to Add Long-Acting Insulin in Diabetic Patients
Add long-acting (basal) insulin when HbA1c remains ≥7.5% (≥58 mmol/mol) despite optimized lifestyle measures and maximal tolerated oral therapy, or immediately when HbA1c ≥10% (≥86 mmol/mol) or blood glucose ≥300 mg/dL (≥16.7 mmol/L). 1, 2
Primary Indication Algorithm
The decision to initiate basal insulin follows this hierarchy:
Immediate Insulin Initiation (Do Not Delay)
- HbA1c ≥10% (≥86 mmol/mol) - insulin is essential at this level 1, 2
- Blood glucose ≥300 mg/dL (≥16.7 mmol/L) 1
- Symptomatic hyperglycemia (polyuria, polydipsia, weight loss) 1
- Possible type 1 diabetes 1
Standard Insulin Initiation
- HbA1c ≥7.5% (≥58 mmol/mol) after optimizing oral agents 2
- HbA1c 1.5-2.0% above individualized goal despite combination therapy 1
Important Caveat: GLP-1 RA Priority
Before initiating basal insulin, consider starting a GLP-1 receptor agonist first if the patient is not already on one, as GLP-1 RAs typically lower HbA1c by 1-2% when added to metformin and avoid the hypoglycemia and weight gain risks of insulin 1. This is particularly important if cardiovascular disease is present, where GLP-1 RAs with proven CVD benefit should be prioritized.
However, when greater glucose-lowering potency is needed (HbA1c ≥10% or ≥86 mmol/mol), basal insulin should be initiated without delay 1.
Practical Initiation Approach
Once the decision is made to start basal insulin:
Starting Regimen
- Begin with once-daily long-acting basal insulin (NPH or long-acting analog like glargine or detemir) 1, 2
- Continue metformin - this combination reduces weight gain, lowers insulin dose requirements, and decreases hypoglycemia compared to insulin alone 2
- Continue other oral agents initially - do not abruptly discontinue to avoid rebound hyperglycemia 2
Starting Dose
Titration Strategy
- Increase by 2 units every 3 days until fasting glucose consistently reaches target 3
- Alternative: increase by 1-2 units or 10-15% of current dose 1
- Target fasting plasma glucose ≤100 mg/dL 4
- If hypoglycemia occurs, reduce dose by 4 units or 10-20% 1, 3
Common Pitfalls to Avoid
Therapeutic inertia is the primary enemy - do not delay treatment intensification when patients are not meeting goals 1. The evidence shows that:
- Most antidiabetic agents achieve near-maximal glucose reduction within several weeks 5
- Optimal control should be attainable within 180 days of treatment initiation 5
- Patients often languish at unsatisfactory HbA1c levels for protracted periods due to clinician conservatism 5
Do not wait too long - real-world data shows that when insulin initiation is delayed until HbA1c ≥9%, only a minority of patients achieve HbA1c <7% with either GLP-1 RA or basal insulin alone 6. The probability of reaching glycemic control is greatest in the first 6-12 months after initiation and diminishes thereafter 6.
Special Situations Requiring Basal-Bolus Insulin from Start
The "5S" situations where basal-bolus insulin (not just basal) should be initiated include 7:
- Severe hyperglycemia (as defined above)
- Symptomatic diabetes with metabolic decompensation
- Sick diabetes (acute illness, surgery, or chronic comorbidity)
- Special situations (pregnancy, childhood, adolescence)
- Secondary diabetes (pancreatic, drug-induced, endocrine disorders)
Evidence Quality Note
The 2025 ADA Standards of Care 1 represent the most current guideline evidence and should frame all decisions. The recommendation to consider GLP-1 RAs before basal insulin (when appropriate) reflects newer evidence about cardiovascular and renal benefits, though this should not delay insulin when HbA1c is markedly elevated. The EADSG guidelines 2 provide concordant recommendations with specific HbA1c thresholds that align with ADA guidance.